NET CONNECT’s Post

Ahead of print Assessment of serum concentration and urinary excretion of tumor necrosis factor receptor 1 and 2 and their potential as markers of immunoglobulin A nephropathy activity Tumor necrosis factor receptor 1 (TNFR1) and 2 (TNFR2) can be cleaved from the cell surface and circulate alone or in combination with tumor necrosis factor alpha (TNF-α). These soluble receptors may play a key role in regulating the inflammatory response. The study aimed to evaluate the role of TNFRs in regulating the inflammatory response in immunoglobulin A nephropathy (IgAN). https://lnkd.in/dDi_Tvnw

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabelled peptide designed to target with receptors overexpressed on tumours. We can use both 90Y-peptide or 177Lu peptides PRRNT is indicated for the treatment of patients with positive expression of sstr2, or metastatic or inoperable NET Eligibility criteria for PRRT : tumor uptake on the Octreoscan being at least as high as the normal liver uptake seen on the planar images Inoperable disease Life expectancy of at least 3–6 months

177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs ESMO - European Society for Medical Oncology #Cancer #ESMO #ESMODailyReporter #ESMOGI24 #OncoDaily #Oncology

A network meta-analysis (DOI: 10.3389/fonc.2024.1344798) of 15 RCTs involving 5,236 HCC patients identifies hepatic arterial infusion chemotherapy combined with sorafenib (HAIC-FO+sorafenib) as the top treatment for advanced HCC with portal vein tumor thrombus (PVTT). This regimen showed the highest overall survival and progression-free survival, indicating a significant advancement in multimodality treatment options for this challenging patient subgroup. #HepatocellularCarcinoma #Pharmacotherapy #PatientOutcome #MedicalResearch

New #JITC article: AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors Monash Health https://bit.ly/46YEIsE

Transarterial chemoembolization plus sorafenib as postop adjuvant therapy in patients with hepatocellular carcinoma with portal vein tumor thrombus resulted in longer recurrence-free survival & overall survival than sorafenib alone. https://ja.ma/3VPibMB

For most patients with ER+, HER2- #MetastaticBreastCancer (MBC), endocrine therapy is the therapeutic backbone throughout their treatment journey and used frequently in regimen combinations. Endocrine therapies target the estrogen receptor pathway, either by blocking receptor binding using an antagonist or by depriving the tumor of estrogen. Click here to discover endocrine therapies that target the estrogen receptor pathway in MBC: https://e.lilly/3Sukz8G #BreastCancer #BCSM #MBC

❓Which 2L treatment option would you recommend for patients w/ #mBC & an ESR1 mutation? Challenge yourself w/ our interactive patient case video series with MCQs & clickable resources! In Episode 1/2 Dr Elisa Agostinetto explores the intricacies of ER+ mBC. Interactive insights, challenging questions, and clickable resources await you on this informative journey! ➡ https://lnkd.in/d5qK2e4F Clinical Takeaways: 🔸 Tumor characteristics influence treatment decisions. 🔸 Liquid biopsy, especially ctDNA analysis, aids in detecting #ESR1 mutations with sensitivity. 🔸 #Elacestrant, the first FDA-approved oral #SERD (Jan 2023), offers a promising choice. 🔸 Oral SERDs show potential in monotherapy and combo treatments with CDK4/6, PI3K, and AKT inhibitors. #MedEd #bcsm #patientcare

(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.

 Adult B-cell precursor acute lymphoblastic leukemia. We report a clinically diagnosed ALL. A sample of a female patient diagnosed as pre B-ALL, according to FAB classifications, was received after the completion of three different protocols of chemotherapy. The conventional cytogenetics analysis by GTG banding revealed the karyotype as 45, XX, -7, der (2) t (2;20) (?;?), t (9;22) (q34;q11), t (12;14) (q?;p?) [12] / 46, XX, t (12;14) (q?;p?) [10] . The dual color FISH using the probe specific for BCR and ABL and WCP probes specific for chromosomes 2, 7, 12, 14 and 20 confirmed the presence of BCR/ABL fusion on der (22) and the presence of the other rearrangements. To further characterize the breakpoints, aMCB was performed, and the final karyotype was redefined as: 45, XX,-7, der (2) (20qter- > 20q13.33::2q21- > 2p14::2q21 > 2qter), t (9;22) (q34;q11), t (12;14) (q12;p12) [12] / 46, XX, t (12;14) (q12;p12) [10]. #casereport #rare #casestudy #banding #gtc